Cyproterone acetate Chemical Properties

Melting point:

200-201°C

Boiling point:

528.8°C (rough estimate)

Density 

1.0677 (rough estimate)

refractive index 

1.4429 (estimate)

storage temp. 

Sealed in dry,Store in freezer, under -20°C

solubility 

Practically insoluble in water, very soluble in methylene chloride, freely soluble in acetone, soluble in methanol, sparingly soluble in anhydrous ethanol.

form 

Solid

color 

White to Off-White

λmax

281nm(MeOH)(lit.)

Merck 

14,2774

InChIKey

UWFYSQMTEOIJJG-KIXORDEXNA-N

SMILES

C[C@@]12C(=CC(=O)[C@@H]3C[C@H]13)C(Cl)=C[C@@]1([H])[C@]3([H])CC[C@@](C(=O)C)(OC(=O)C)[C@@]3(C)CC[C@]21[H] |&1:1,6,8,12,14,18,26,30,r|

EPA Substance Registry System

3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)- (427-51-0)

Safety Information

Hazard Codes 

Xn,Xi

Risk Statements 

20/21/22-40-36/37/38

Safety Statements 

22-36-26

WGK Germany 

3

RTECS 

GZ2230000

HS Code 

29372900

Hazardous Substances Data

427-51-0(Hazardous Substances Data)

MSDS

• Language:English Provider:SigmaAldrich

Cyproterone acetate Usage And Synthesis

Description

Cyproterone acetate (CPA) is an androgen receptor antagonist. It binds to human androgen receptors (K_i = 14 nM) and inhibits dihydrotestosterone-induced androgen receptor activation in CV-1 cells (IC₅₀ = 26 nM). CPA (30 mg/kg) decreases ventral prostate weight in castrated immature rats. It also suppresses accessory sexual glands and fertility in adult male rats when administered at a dose of 10 mg/kg. CPA (0.3 μM) also induces apoptosis in primary adult female rat hepatocytes. Formulations containing cyproterone acetate have been used in the treatment of androgenization in females.

Chemical Properties

Crystalline Solid

Originator

Androcur ,Schering,W. Germany,1973

Uses

Cyproterone acetate (CPA) has been shown to exert gestagenic and glucocorticoid effects. Because it inhibits the negative diencephalic pituitary testicular feedback system, it lowers luteinizing hormone (LH) and testosterone production and plasma levels. cyproterone acetate is both an anti-androgen and a progestogen. CPA is used in combined birth control pills, in the treatment of androgen-dependent skin and hair conditions such as acne (Combined with estrogen), seborrhea, excessive hair growth, and scalp hair loss, high androgen levels, in transgender hormone therapy, to treat prostate cancer, to reduce sex drive in sex offenders or men with paraphilias or hypersexuality, to treat early puberty, and for other uses. It is used both at low doses and at higher doses.

Definition

ChEBI: Cyproterone acetate is a steroid ester resulting from the formal condensation of the carboxy group of acetic acid with the 17-hydroxy group of cyproterone. It is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. It has a role as an androgen antagonist, a progestin and a geroprotector. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid, a chlorinated steroid, a steroid ester and an acetate ester. It is functionally related to a cyproterone.

Indications

Cyproterone acetate is a progestational antiandrogen that blocks androgen receptor binding and suppresses androgen-sensitive tissues. It is available in a topical form in Europe for the treatment of hirsutism.

Manufacturing Process

2.34 g of 1,2α-methylene-δ4,6-pregnadiene-17α-ol-3,20-dione-17-acetate are dissolved in 18.25 cc of ethylene chloride which contains 844 rng of perbenzoic acid. The solution is stored for 16 hours at +5°C and 7 hours at room temperature. It is then diluted with methylene chloride and, with aqueous ferrous sulfate solution, sodium bicarbonate solution and with water washed until neutral.
The organic phase is dried over sodium sulfate and then concentrated to dryness. 1.62 g of the thus obtained crude 1,2α-methylene-6,7α-oxido-δ4- pregnene-17α-ol-3,20-dione-17-acetate are dissolved in 109 cc of glacial acetic acid. This solution is then saturated at room temperature with hydrogen chloride gas and stored for 20 hours, It is then diluted with methylene chloride and washed with water until neutral.
The organic phase is dried over sodium sulfate and then concentrated to dryness. The thus obtained crude 6-chloro-1α-chloromethyl-δ4,6-pregnadiene17α-ol-3,20-dione-17-acetate is heated to boiling in 20 cc of collidine for 20 minutes under nitrogen. After dilution with ether it is washed with 4 N hydrochloric acid and washed with water until neutral.
After drying over sodium sulfate and concentration to vacuum the remaining residue is subjected to chromatography over silica gel. Using a benzene-ethyl acetate mixture (19:1) there is eluated 900 mg of 6-chloro-1,2α-methyleneδ4,6-pregnadiene-17α-ol-3,20-dione-17-acetate, which upon recrystallization from isopropyl ether melts at 200° to 201°C.

Therapeutic Function

Antiandrogen

Mechanism of action

The mechanism of action of Cyproterone acetate at the molecular level has never been described conclusively. Studies have found that in rat ventral prostate nuclei, CPA interferes with androgen binding to the androgen receptor. It is possible that CPA interferes with the translocation of the androgen receptor from the cytoplasm to the nuclear compartment. At the transcription level, the effects of CPA also include a reduction of androgen-dependent cellular functions, such as a reduction of acid phosphatase, prostate-specific androgen, and androgen-dependent enzymes such as 5-a-reductase[1].

Side effects

Vbreast tenderness and swelling. Tiredness and weakness (fatigue). Depression or mood changes. Hot flushes or sweats. Swelling in parts of the body (fluid build up). Weight changes. Liver changes (you will have regular blood tests to check for this). Shortness of breath.

Metabolism

Cyproterone is metabolised by various pathways including hydroxylation and conjugation; about 35% of a dose is excreted in urine, the remainder being excreted in the bile. The principal metabolite, 15β-hydroxycyproterone, has anti-androgenic activity

References

[1] Schr?der F, et al. Cyproterone Acetate-Mechanism of Action and Clinical Effectiveness in Prostate Cancer Treatment. Cancer, 1993; 72: 3810-3815.

Cyproterone acetate(427-51-0)Related Product Information

• 1-Methoxy-2-propyl acetate
• Methyl acetate
• Tocopheryl acetate
• Leuprorelin acetate
• Ethylene glycol monoethyl ether acetate
• Vinyl acetate
• Glatiramer acetate
• POLY(VINYL ACETATE)
• Isopropyl acetate
• Sodium acetate
• 2-Butoxyethyl acetate
• Ethyl acetate
• Butyl acetate
• CHLOROPHOSPHONAZO III
• Chlormadinone acetate
• Pregna-4,6-diene-3,20-dione
• ACETATE
• Cyproterone Acetate 427-51-0 /Base